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THE LANCET 
patients have coinfekon with Hw. Poor health-care 
management and a disrupted society seem to account for the 
worsening epidemiological situation. The professional skill 
of physicians and nurses is, I believe, equal to that of the 
west, but the health-care administration is disastrous and 
communication networks are badly structured and 
inefficient. For these reasons I would like to invite those with 
an interest in TB to come and work with us. We can share 
with them our willingness to act. 
Traian Mihaescu 
Clinic of Pulmonary Diseases. 30 Dr I Cihac St, lasi 6600. Romania 
Sm-Few organisations from the West have first-hand 
experience of the difficulties of controlling tuberculosis flB) 
in the former Soviet Union. Bums and colleagues mention 
the problems faced by a team from Project Hope who are 
working on TB in Atyrau, Kazakhstan. MERLIN (Medical 
Emergency Relief Intemational) has similar experience in 
the Tomsk region in Siberia. 
Cure rates in Tomsk tend to be low. The incidence of ne& 
cases of TB in 1993, in a population of about 1000 000, was 
53 per 100 O00 and the prevalence was 390 per 100 O00 
(although this figure might contain some cases with inactive 
disease). The wide discrepancy between incidence and 
prevalence suggests that there is a large pool of chronic cases 
who could pose a major clinical social and economic 
problem. Among different groups, the incidences were 
highest in the most socially disadvantaged (reaching 400 per 
100 O00 in prisoners) and among men between the ages of 
20 and 49. 
The team working in Atyrau reported high levels of 
resistance to antituberculosis drugs and similar results were 
found in Tomsk. However, the methods used to measure 
resistances in the Tomsk area are not standard, and a 
collaborative study between MERLIN and the laboratories 
in Tomsk has been set up. Isolates from patients in Tomsk 
have been brought to the UK for analysis by a reference 
laboratory. 
Multidrug resistance and low cure rate can probably be 
attributed to the treatment regimens in the Tomsk area. The 
regimen calls for three drugs to be given for two or three 
months, depending on the patient's condition. The drugs 
may be changed during this period. Patients are then 
declared inactive and are given two months' isoniazid 
monotherapy in spring and ,autumn for the following two 
years. Drug shortages mean that the initial treatment is often 
intermittent and incomplete. As an adjunct to drug therapy, 
and in relapse, other treatments include intrabronchial 
instillation of isoniazid (via a Foley catheter passed down the 
nose) and galvanisation (application of a weak electric 
current across the chest during intravenous isoniazid). If 
there is no cure after these treatments (defined locally as 
closure of cavities on radiography) then 28% of patients 
undergo thoracic surgery, mostly lobectomy. 
The TB physicians in the Tomsk region are able and 
committed, but are frustrated by inadequate drug supplies. 
Screening and preventive services consume large amounts of 
resources. Children receive BCG five days after birth and 
thereafter receive an annual Mantoux test. Individuals may 
be given BCG every seven years until they are 35. All adults 
are supposed to be screened annually by mass miniature 
radiography but the uptake is much higher by the urban 
employed than by risk groups-the unemployed, the 
homeless, and the elderly. The microbiology services are 
primitive, under-resourced and under-used. The MERLIN 
programme, which has been approved by WHO, is offering 
information and resources to physicians in Tomsk to' adopt 
WHO protocols and strategies for diagnosis and treatment. 
With funding from the European Commission and Glaxo, 
we have supplied suEcient drugs for all patients in the 
region for 3 years and are re-equipping the microbiology 
services. We agree with Bums and his colleagues that 
financial support for national TB programmes in Russia and 
the former Soviet Union is vital. We believe that the West 
should take a leading role in providing both funding and 
information. 
E M Tayler, T D Healing, C P Besse 
MERLIN, 49 Portland Road, London W11, UK 
Effect of Edmonston-Zagreb high-titre vaccine 
on nutritional status qt* Cd,ci9 v &$,y&=,;; y 2  
SIR-Our original study in Senegal showed that high-titre 
measles vaccines were increasing the risk of death of 
children,' although the vaccines provided a significant - 
protection against the disease.* After our publication, WHO 
asked for an independent comparative analysis of available 
data, which confirmed our findings. Since then, WHO no 
longer recommends the use of the Edmonston-Zagreb high- 
titre vaccine (EZ-HT) .3 
The negative effect of the EZ-HT vaccine on child 
survival seemed to be higher for girls than for boys. The sex 
differences were not significant in our study (relative risk 
[RR]=1*20, ~ ~ 0 . 4 9 7  in the EZ-HT group), but were found 
to be similar in other studies. When examined by sex, the 
differences in mortality in the Senegal study were significant 
for female children but not for male. In a sense, this finding 
was expected since measles shows an excess female mortality 
worldwide." However, we felt that the vaccines were also 
deleterious for male children. 
Data showing an effect of the EZ-HT vaccine on 
numtional status are now a~ailable.~ The study was 
conducted among the survivors of the participants in the 
original study, and in fact was a natural follow-up of the 
randomised vaccine trial and took place within two months 
after the updating of the survival status in October, 1990. 
Children bom between Feb 1, 1988, and Sept 30, 1988 
(monthly birth cohorts 13-20), who had received the EZ- 
HT at 5 months or the standard Schwarz vaccine at 10 
months, who were still resident, were investigated in 
November and December, 1990. Their weight, height, and 
arm circumference were measured by trained personnel. Age 
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was known for all children. Standardised indices of 
numtional status (Z-score) were computed with the US 
national (NCHS) standard: height for age, weight for age, 
weight for height. A cutoff of -2 SD was taken as the 
threshold for poor nutritional status. Since the children were 
aged 26-33 months (when arm circumference is virtually 
constant) the plain value of arm circumference was used, 
and the standard cutoff of 125 mm was taken as a criterion 
for poor nutritional status. 
There was no excess prevalence of stunting (height for age 
lower than -2 SD) in the group that received EZ-HT 
vaccine (RR 1-03, 95% CI 0-88-1.21, p=0-711). However, 
there was a major effect on wasting. Children who had 
received EZ-HT vaccine at 5 months had 2-85 times more 
chance of being under the -2 SD thresholds of weight for 
height than their counterparts who received the standard 
vaccine at 10 months (95% CI 1.34-6.06, p=0-007). 
Similarly, children who received the EZ-HT vaccine at 5 
months were 1.36 times more likely to be under the -2 SD 
threshold of weight for age than control children (1.10-1.68, 
p=0.005). Differences according to arm circumference were 
in the same direction, but were not statistically significant. 
However, all 5 children with an arm circumference lower 
than 110 mm (severe malnutrition) were in the EZ-HT 
group (p=O.001).* 
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hiore importantly, both sexes showed a consistent and 
similar increase in wasting (low weight for height) in the EZ- 
HT group. Here, the differences were more striking in males 
and significant only among males. (3.16, 1-17-8.57, 
p=0.023). The same was true for weight for age (141, 
1.05-1.89, p=0.023). The differences may look small: for 
instance, 49 per 1000 in the EZ-HT group versus 17 per 
1000 for low weight for height. However, assuming that this 
difference reveals a group of children at high risk of death, 
this will be translated into an absolute difference of 32 per 
1000, which is similar to the absolute difference in mortality 
between the two groups (47 per 1000 at age 30 months). 
The fact that a low nutritional status seemed to be more 
pronounced in boys may be attributable to a selection effect. 
Since girls were more likely to die before the nutritional 
assessment, the sample may have been biased towards fewer 
surviving girls and more surviving boys suffering from the 
late effect of the vaccine. In any case, these findings 
mder!i?e the f x t  that the EZ-HT vaccine was deleterious at 
the same time for both sexes and that stopping its use for 
everybody was wise. 
Michel Garenne 
HaNard Center for Population and Developmental Studies. Cambridge. 
MA 02138. USA 
Table of full results available from The Lancer or from the author, on 
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Frequency of infection in plateau-phase 
multiple myeloma 
Sm-Chapel et al (April 30, p 1059) report a small 
randomised trial evaluating the effect of prophylactic 
intravenous immunoglobulin in the prevention of infection 
in plateau-phase multiple myeloma. As rationale for this trial 
they cite an earlier study in which they found that three- 
quarters of all serious infections in myeloma patients 
occurred more than three months after diagnosis and initial 
chemotherapy.‘ Other workersy2 and our own data do not, 
however, support this observation. 
We evaluated the frequency of infection in 114 patients 
followed for 2892 plateau months (mean 25.1, range 
15157) .  With Chapel and co-workers’ criteria, there were 
four episodes of septicaemia, three of pneumonia, and four 
of other serious infections in 8 patients (7%), with a 
frequency of one serious or life threatening infection every 
271 plateau months. Our practice is not to routinely use 
prophylactic intravenous immunoglobulin and to reserve this 
agent for patients with confirmed‘ recurrent bacterial 
 infection^.^ In fact, in this cohort of plateau-phase patients, 
only 1, with recurrent respiratory tract infection, fulfilled 
these criteria and was receiving both prophylactic 
immunoglobuliri and antibiotics. By contrast with our data, 
the frequency of such infections in the placebo arm of 
Chapel’s study was one infection every 13.4 months, 
whereas in the immunoglobulin arm it was one infection per 
26.2 months. 
One explanation for this striking discrepancy in infection 
rates might be parient selection and the definition of plateau. 
Despite the title of their article, only 44 of Chapel and 
colleagues’ patients actually fulfilled one of the key criteria 
for plateau phase-ie, stable Paraprotein for at least 6 
months. The others were thought to have stable disease, 
although the exact definition of this !itate is not provided. By 
contrast, all our patients were assigned to plateau-phase by 
standard criteria.* 
Our data, unlike those of Chapel, indicate that in true 
plateau-phase myeloma the incidence of serious bacterial 
infection is very IOW and would not justify the routine use of 
prophylactic intravenous immuwgiobulin. Patients with 
recurrent documented bacterial infection (especially 
polysaccharide encapsulated bacteria) may, however, benefit 
from such therapy. 
Leonie Snowdon, John Gibson. Doug E loshua 
Myeloma Research Grow. HaematoWy DeParfnes. Royal Prince Alfred Hospital, 
campereown. F?Ç&! 2051-1. Australia 
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Arthropathy in thalassaenria patients 
receiving deferiprone 
SIR-Berkovitch and colleagues b 11, p 1471) report 
three further cases of arthropatlq b patients receiving the 
oral iron chelator L, (deferiprone2- This complication was 
first reported in 4 of 13 cases ~TS& by Baden and co- 
workers,‘ and subsequent cases k2-e Óeen described (refs 2, 
3, and Al-Refaie et al. BrJ HU” 1994; 86 (suppl 1): 5 
(14)). Berkovitch and colleagua auclude by stating that 
future mals of deferiprone will h w  the frequency of 
arthropathy in larger numbers ofpãknrs. There are now at 
least eight published reports c6 long-term trials of 
deferiprone therapy recently r e a  and updated4 giving 
an overall frequency of arthrop- of 16.5% (41 of 248 
patients). 
Berkovitch and co-workers’ also accord with 
those’ of previous tha~ %e is no correlation 
between the presence or not of &qathy and positive tests 
for antinuclear factor or rheumax2 factor. They state that 
synovial fluid aspirated from k aints in their patients 
revealed “low concentrations of Mzzprone uncomplexed to 
iron”. They provide no data fe -vial fluid deferiprone 
concentrations, nor do they mnr.n how deferiprone was 
detected and measured, or how glucuronidated, and 
iron-complexed deferiprone we= %guished. It is unclear 
when deferiprone was taken by zmr.!~ in relation to the time 
of joint aspiration. There is rx - m o n  of the relation of 
synovial fluid deferiprone c0nc-n to the simultaneous 
serum concentration of deferiFre In a previous abs@act5 
they stated that synovial defezqze concentrations were 
similar to those in s e m  n n  complexes being 
undetectable. Whether the arkpr,Srhy is caused by the 
formation of 1/1 and li2 iroddek-one complexes capable 
of gener?ting fkee radicals (as k a v i t c h  suggests) or to 
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